scholarly journals Economic burden of eating disorders in South Korea

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Sang Min Lee ◽  
Minha Hong ◽  
Saengryeol Park ◽  
Won Sub Kang ◽  
In-Hwan Oh
Keyword(s):  
Eating Disorders ◽  
South Korea ◽  
Economic Burden ◽  
Indirect Costs ◽  
Economic Cost ◽  
Medical Expenditure ◽  
Treatment Prevalence ◽  
Total Economic Cost ◽  
Total Treatment ◽  
The Cost

Abstract Background Few studies have investigated the epidemiology of eating disorders using national representative data. In this study, we investigated the treatment prevalence and economic burden of eating disorders in South Korea. Methods The aim of this study was to estimate the treatment prevalence and the medical expenditure of diagnosed eating disorders (ICD F50.x) in South Korea between 2010 and 2015. We also examined the economic costs of eating disorders, including the direct medical cost, direct non-medical costs, and indirect costs, in order to calculate the economic burden of such disorders. Results The total treatment prevalence of eating disorders in South Korea was 12.02 people (per 100,000) in 2010, and 13.28 in 2015. The cost of medical expenditures due to eating disorders increased from USD 1229724 in 2010 to USD 1843706 in 2015. The total economic cost of eating disorders was USD 5455626 in 2015. In 2015, the economic cost and prevalence of eating disorders was the highest in the 20–29 age group. Conclusions The results showed the eating disorders are insufficiently managed in the medical insurance system. Further research is therefore warranted to better understand the economic burdens of each type of eating disorder.

scholarly journals Economic burden of eating disorders in South Korea

2020 ◽  
Author(s):  
Sang Min Lee ◽  
Minha Hong ◽  
Saengryeol Park ◽  
Won Sub Kang ◽  
In-Hwan Oh
Keyword(s):  
Eating Disorders ◽  
South Korea ◽  
Economic Burden ◽  
Indirect Costs ◽  
Economic Cost ◽  
Medical Expenditures ◽  
Medical Expenditure ◽  
Total Prevalence ◽  
Total Economic Cost ◽  
The Cost

Abstract BackgroundFew studies have investigated the epidemiology of eating disorders using national representative data. In this study, we investigated the prevalence and economic burden of eating disorders in South Korea.MethodsThe aim of this study was to estimate the medical expenditure of diagnosed eating disorders (ICD F50.x) in South Korea between 2010 and 2015. We also examined the economic costs of eating disorders, including the direct medical cost, direct non-medical costs, and indirect costs, in order to calculate the economic burden of such disorders.ResultsThe total prevalence of eating disorders in South Korea was 12.02 people (per 100 000) in 2010, and 13.28 in 2015. The cost of medical expenditures due to eating disorders increased from USD 1 229 724 in 2010 to USD 1 843 706 in 2015. The total economic cost of eating disorders was USD 5 455 626 in 2015. In 2015, the economic cost and prevalence of eating disorders was the highest in the 20–29 age group.ConclusionsThe results showed the eating disorders are insufficiently managed in the medical insurance system. Further research is therefore warranted to better understand the economic burdens of each type of eating disorder.

scholarly journals Economic burden of Eating disorders in South Korea

2020 ◽  
Author(s):  
Sang Min Lee ◽  
Minha Hong ◽  
Saengryeol Park ◽  
Won Sub Kang ◽  
In-Hwan Oh
Keyword(s):  
Eating Disorders ◽  
South Korea ◽  
Direct Medical Cost ◽  
Medical Cost ◽  
Economic Burden ◽  
Disease Burden ◽  
Indirect Costs ◽  
Economic Cost ◽  
Age Group ◽  
Total Prevalence

Abstract Objective Few studies have investigated the epidemiology of eating disorders using national representative data. In this study, we investigated the prevalence and economic burden of eating disorders in South Korea.Method The aim of this study was to estimate the disease burden of diagnosed eating disorders (ICD F50.x) over a six-year period between 2010 and 2015, in South Korea. The direct medical cost, direct non-medical costs, and indirect costs resulting from eating disorders were estimated in order to calculate the economic burden of such disorders.Results The total prevalence was 12.02 people (per 100,000) in 2010, and 13.28 in 2015. The economic cost of eating disorders was estimated to be USD5,727,843 in 2010 and USD5,338,752 in 2015. The economic cost and prevalence of eating disorders was the highest in the 20–29 age group.Conclusion The results showed the eating disorders are insufficiently managed in the medical insurance system. The further research is warranted to better understand the economic burdens of each eating disorders.

scholarly journals Typhoid and Paratyphoid Cost of Illness in Nepal: Patient and Health Facility Costs From the Surveillance for Enteric Fever in Asia Project II

2020 ◽  
Vol 71 (Supplement_3) ◽  
pp. S306-S318 ◽  
Author(s):  
Nelly Mejia ◽  
Taiwo Abimbola ◽  
Jason R Andrews ◽  
Krista Vaidya ◽  
Dipesh Tamrakar ◽  
...  
Keyword(s):  
Healthcare Provider ◽  
Cost Of Illness ◽  
Economic Burden ◽  
Enteric Fever ◽  
Healthcare Providers ◽  
Indirect Costs ◽  
Economic Cost ◽  
Prevention Measures ◽  
Illness Onset ◽  
The Cost

Abstract Background Enteric fever is endemic in Nepal and its economic burden is unknown. The objective of this study was to estimate the cost of illness due to enteric fever (typhoid and paratyphoid) at selected sites in Nepal. Methods We implemented a study at 2 hospitals in Nepal to estimate the cost per case of enteric fever from the perspectives of patients, caregivers, and healthcare providers. We collected direct medical, nonmedical, and indirect costs per blood culture–confirmed case incurred by patients and their caregivers from illness onset until after enrollment and 6 weeks later. We estimated healthcare provider direct medical economic costs based on quantities and prices of resources used to diagnose and treat enteric fever, and procedure frequencies received at these facilities by enrolled patients. We collected costs in Nepalese rupees and converted them into 2018 US dollars. Results We collected patient and caregiver cost of illness information for 395 patients, with a median cost of illness per case of $59.99 (IQR, $24.04–$151.23). Median direct medical and nonmedical costs per case represented ~3.5% of annual individual labor income. From the healthcare provider perspective, the average direct medical economic cost per case was $79.80 (range, $71.54 [hospital B], $93.43 [hospital A]). Conclusions Enteric fever can impose a considerable economic burden on patients, caregivers, and health facilities in Nepal. These new estimates of enteric fever cost of illness can improve evaluation and modeling of the costs and benefits of enteric fever–prevention measures.

scholarly journals The Direct and Indirect Costs of Colorectal Cancer in Vietnam: An Economic Analysis from a Social Perspective

2020 ◽  
Vol 18 (1) ◽  
pp. 12
Author(s):  
Binh Thang Tran ◽  
Kui Son Choi ◽  
Thanh Xuan Nguyen ◽  
Dae Kyung Sohn ◽  
Sun-Young Kim ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Economic Burden ◽  
National Level ◽  
Indirect Costs ◽  
Economic Cost ◽  
Income Loss ◽  
Screening Programs ◽  
Incidence And Mortality ◽  
Total Economic Cost ◽  
Advanced Stages

The incidence and mortality of colorectal cancer (CRC) has increased rapidly in Vietnam, but the economic burden of this disease has never been estimated. We estimate the direct and indirect cost of CRC patients in Vietnam in 2018 using a prevalence-based approach and human capital method. The total economic cost of CRC was VND 3041.88 billion (~$132.9 million), representing 0.055% of the 2018 gross domestic product. Notably, indirect costs comprised 83.58 % of the total cost, 82.61% of which is future income loss, because CRC occurs during productive years. The economic burden of CRC in Vietnam is substantial. The medical cost for CRC diagnosis and treatment is higher for younger patients and for those in advanced stages. Strategies to decrease the economic burden of CRC at the patient and national level, such as screening programs, should be developed and implemented in Vietnam.

scholarly journals Economic burden of smoking attributed illnesses in Pakistan

2020 ◽  
Author(s):  
Muhammad Arif Nadeem Saqib ◽  
Ashar Malik ◽  
Ibrar Rafique ◽  
Faiz Ahmed Raza ◽  
Obaidullah ◽  
...  
Keyword(s):  
Tobacco Control ◽  
Economic Burden ◽  
Indirect Costs ◽  
Economic Cost ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Policy Interventions ◽  
Tobacco Control Policies ◽  
Total Economic Cost ◽  
Disease Specific

ABSTRACTBackgroundThe estimates of economic burden due to smoking attributed illnesses provide an opportunity to assess its overall impact on the economy and generate evidence for public health policy interventions for tobacco control. In this study, we estimated out of pocket expenditures on tobacco attributed illnesses and smoking attributable burden in Pakistan.MethodsWe used a prevalence-based disease-specific cost approach by including three major tobacco attributed illnesses i.e. lung cancer, chronic obstructive pulmonary disease, and cardiovascular diseases. Our analysis included out of pocket healthcare expenditures including direct and indirect costs which were estimated by interviewing the patients of selected illnesses. The smoking-attributable expenditure was calculated by the WHO tool kit.ResultsIn 2018, the economic burden attributed to smoking related illnesses was Rs 192 billion (USD 1.3 billion). Smoking-attributable expenditure on cardiovascular disease was Rs 123 billion (USD 0.9 billion) which was 69% of the total economic cost of tobacco attributed illnesses in Pakistan. The economic cost in males was nearly three times higher than females.ConclusionsOur study showed a significant economic burden due to tobacco attributed illnesses in Pakistan which can be prevented by implementing tobacco control policies effectively.

scholarly journals Healthcare Expenditures Associated with Heart Failure in Saudi Arabia: A Cost of Illness Study

Healthcare ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 988
Author(s):  
Ahmed Alghamdi ◽  
Eman Algarni ◽  
Bander Balkhi ◽  
Abdulaziz Altowaijri ◽  
Abdulaziz Alhossan
Keyword(s):  
Heart Failure ◽  
Saudi Arabia ◽  
Cost Of Illness ◽  
Economic Burden ◽  
Indirect Costs ◽  
Health Care Expenditures ◽  
Decision Makers ◽  
Hospitalization Costs ◽  
Illness Study ◽  
The Cost

Heart failure (HF) is considered to be a global health problem that generates a significant economic burden. Despite the growing prevalence in Saudi Arabia, the economic burden of HF is not well studied. The aim of this study was to estimate the health care expenditures associated with HF in Saudi Arabia from a social perspective. We conducted a multicenter cost of illness (COI) study in two large governmental centers in Riyadh, Saudi Arabia using 369 HF patients. A COI model was developed in order to estimate the direct medical costs associated with HF. The indirect costs of HF were estimated based on a human capital approach. Descriptive and inferential statistics were analyzed. The direct medical cost per HF patient was $9563. Hospitalization costs were the major driver in total spending, followed by medication and diagnostics costs. The cost significantly increased in line with the disease progression, ranging from $3671 in class I to $16,447 in class IV. The indirect costs per working HF patient were $4628 due to absenteeism, and $6388 due to presenteeism. The economic burden of HF is significantly high in Saudi Arabia. Decision makers need to focus on allocating resources towards strategies that prevent frequent hospitalizations and improve HF management and patient outcomes in order to lower the growing economic burden.

scholarly journals National Economic Burden Associated with Management of Periodontitis in Malaysia

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Tuti Ningseh Mohd Dom ◽  
Rasidah Ayob ◽  
Khairiyah Abd Muttalib ◽  
Syed Mohamed Aljunid
Keyword(s):  
Societal Perspective ◽  
Economic Burden ◽  
Census Data ◽  
Adult Population ◽  
National Level ◽  
Indirect Costs ◽  
Treatment Costs ◽  
High Prevalence ◽  
National Economic ◽  
The Cost

Objectives. The aim of this study is to estimate the economic burden associated with the management of periodontitis in Malaysia from the societal perspective.Methods. We estimated the economic burden of periodontitis by combining the disease prevalence with its treatment costs. We estimated treatment costs (with 2012 value of Malaysian Ringgit) using the cost-of-illness approach and included both direct and indirect costs. We used the National Oral Health Survey for Adults (2010) data to estimate the prevalence of periodontitis and 2010 national census data to estimate the adult population at risk for periodontitis.Results. The economic burden of managing all cases of periodontitis at the national level from the societal perspective was approximately MYR 32.5 billion, accounting for 3.83% of the 2012 Gross Domestic Product of the country. It would cost the nation MYR 18.3 billion to treat patients with moderate periodontitis and MYR 13.7 billion to treat patients with severe periodontitis.Conclusion. The economic burden of periodontitis in Malaysia is substantial and comparable with that of other chronic diseases in the country. This is attributable to its high prevalence and high cost of treatment. Judicious application of promotive, preventive, and curative approaches to periodontitis management is decidedly warranted.

Abstract 19839: Clinical and Economic Burden of Rheumatic Heart Disease in Low-Income Nations: Estimating the Cost-of-Illness in India and Uganda

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Alexander T Sandhu ◽  
Kathikeyan G ◽  
Ann Bolger ◽  
Emmy Okello ◽  
Dhruv S Kazi
Keyword(s):  
Heart Disease ◽  
Rheumatic Heart Disease ◽  
Cost Of Illness ◽  
Economic Burden ◽  
Indirect Costs ◽  
Medical Costs ◽  
Discrete State ◽  
Direct Medical Costs ◽  
The Cost ◽  
Rheumatic Heart

Introduction: Rheumatic heart disease (RHD) strikes young adults at their peak economic productivity. Defining the global economic burden of RHD may motivate investments in research and prevention, yet prior approaches considering only medical costs may have underestimated the cost of illness. Objectives: To estimate the clinical and economic burden of RHD in India and Uganda. Outcomes were disability-adjusted life years (DALYs), direct medical costs, and indirect costs due to disability and premature mortality (2012 USD). Methods: We used a discrete-state Markov model to simulate the natural history of RHD using country-, age-, and gender-specific estimates from the literature and census data. We estimated direct medical costs from WHO-CHOICE and Disease Control and Prevention 3 publications. We conservatively estimated indirect costs (lost earnings and imputed caregiver costs) from World Bank data using novel economic methods. Results: In 2012, RHD generated 6.1 million DALYs in India and cost USD 10.7 billion (Table 1), including 1.8 billion in direct medical costs and 8.9 billion in indirect costs. During the same period, RHD produced 216,000 DALYs in Uganda, and cost USD 414 million, and, as in India, indirect costs represented the majority (88%) of the cost of illness. In both countries, women accounted for the majority (71-80%) of the DALYs; in Uganda, women bore 75% of the total cost. In sensitivity analyses, higher progression rates for subclinical disease doubled direct costs and DALYs. Conclusion: RHD exacts an enormous toll on the populations of India and Uganda, and its economic burden may be grossly underestimated if indirect costs are not systematically included. Women bear a disproportionate clinical burden from pregnancy-related complications. These results suggest that effective prevention and screening of RHD may represent a sound public health investment, particularly if targeted at high-risk subgroups such as young women.

Modeling the likely economic cost of non-adherence to TB medicines in the Philippines

2020 ◽  
Vol 24 (9) ◽  
pp. 902-909
Author(s):  
D. Collins ◽  
H. Lam ◽  
H. Firdaus ◽  
J. Antipolo ◽  
P. Mangao
Keyword(s):  
Economic Impact ◽  
Economic Burden ◽  
Economic Cost ◽  
The Philippines ◽  
Economic Costs ◽  
Loss To Follow Up ◽  
The World ◽  
Mdr Tb ◽  
The Cost

SETTING: The Philippines has a population of over 90 million people and is one of the 22 highest TB burden countries in the world.OBJECTIVE: To understand the economic cost of non-adherence to TB medicines due to loss to follow up and stock-outs in the Philippines.DESIGN: Data were collected on the economic costs of non-adherence to TB medicines and a model was developed to show those costs under different scenarios.RESULTS: The model showed that as many as 1958 and 233 persons are likely to have died as a result of DS-TB and MDR-TB loss to follow up, respectively, and 588 persons are likely to have died as a result of TB medicine stock outs. The related economic impact in each case is likely have been to be as much as US$72.2 million, US$13.4 million and US$21.0 million, respectively.CONCLUSION: The economic costs of non-adherence to TB medicines due to loss to follow-up and stock-outs represent a significant economic burden for the country and it is likely that the cost of addressing these problems would be much less than this burden and, therefore, a wise investment.

scholarly journals Economic burden of cancers in Taiwan: a direct and indirect cost estimate for 2007–2017

BMJ Open ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. e036341
Author(s):  
Shao-Yi Huang ◽  
Ho-Min Chen ◽  
Kai-Hsin Liao ◽  
Bor-Sheng Ko ◽  
Fei-Yuan Hsiao
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Resource Allocation ◽  
Economic Burden ◽  
Indirect Costs ◽  
Female Breast Cancer ◽  
Cost Driver ◽  
Female Breast ◽  
Driver Analysis ◽  
The Cost

ObjectiveCancers result in significant economic burdens on patients, health sectors and society. Reliable burden estimates will help guide resource allocation. This study aimed to perform a nationwide cost analysis of the direct and indirect costs of the top ten most costly cancers, and acute coronary syndrome (ACS), as a comparison, in Taiwan.SettingA population-based cohort study.ParticipantsIn total, 545 221 patients with newly diagnosed cancer (lung cancer, female breast cancer, colorectal cancer, liver cancer, oral cancer, leukaemia, prostate cancer, non-Hodgkin's lymphoma, gastric cancer and oesophageal cancer) and 170 879 patients with ACS between 2007 and 2014 were identified.Primary and secondary outcome measuresDirect medical costs were calculated from claims recorded in the National Health Insurance Research Database . Indirect costs, comprising morbidity-associated and mortality-associated productivity losses, were estimated from public life expectancy, average wage and employment data. The costs incurred in the 3 years after diagnosis were assessed. As a comparison, the cost of ACS was also estimated using the same study frame. A cost driver analysis was conducted to identify factors impacting cancer costs.ResultsThe cancers with the highest mean direct medical costs and total costs were leukaemia (US$28 464) and oesophageal cancer (US$81 775), respectively. Indirect costs accounted for over 50% of the total economic burden of most cancers, except for prostate cancer and female breast cancer. The costs of ACS were lower than those of most cancers. From the cost driver analysis, older age at diagnosis significantly (p<0.05) decreased the total cost of cancer; in contrast, male, tumour metastasis, comorbidities and treatment in medical centres increased the costs.ConclusionsThis study demonstrates the comprehensive economic burden of the top 10 most costly cancers in Taiwan. These results are valuable for optimising healthcare resource allocation.

Sign in / Sign up

Export Citation Format

Share Document